改良EASIX预测CAR-T后重度细胞因子释放综合征与神经毒性
该研究纳入118例接受CAR-T治疗的成人患者,评估EASIX及两种改良公式对重度CRS和ICANS的预测价值。三种公式预测效能相似,但仅m-EASIX为疾病反应的显著预测因子,且可在重度症状出现前区分高危患者。
要点
- m-EASIX可在重度CRS症状出现前识别高危患者。
- 低血小板和高CRP是唯一与重度CRS/ICANS独立相关的变量。
- 仅m-EASIX是疾病反应的显著预测因子。
核心结论
- m-EASIX可作为临床工具潜在指导CAR-T相关重度毒性高危患者的个体化管理。
研究设计与样本
- 回顾性纳入118例成人患者,53例B-ALL接受1928z CAR-T,65例DLBCL接受axi-cel或tisa-cel。
主要发现
- 三种公式对重度CRS和ICANS的预测效能相似。
- 低血小板和高CRP是唯一与重度CRS/ICANS单独相关的变量。
- 仅m-EASIX是疾病反应的显著预测因子。
- m-EASIX在淋巴细胞清除时AUC为80.4%,第-1天为73.0%,第+1天为75.4%,可区分后续发生重度CRS的患者。
- 第+3天m-EASIX对重度ICANS的AUC为73%。
临床怎么用
- 围CAR-T输注期计算m-EASIX有助于早期识别重度CRS和ICANS高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients who develop chimeric antigen receptor (CAR) T-cell-related severe cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) exhibit hemodynamic instability and endothelial activation. The EASIX (Endothelial Activation and Stress Index) score (lactate dehydrogenase [LDH; U/L] × creatinine [mg/dL]/platelets [PLTs; 109 cells/L]) is a marker of endothelial damage that correlates with outcomes in allogeneic hematopoietic cell transplantation. Elevated LDH and low PLTs have been associated with severe CRS and ICANS, as has C-reactive protein (CRP), while increased creatinine is seen only in a minority of advanced severe CRS cases. We hypothesized that EASIX and 2 new modified EASIX formulas (simplified EASIX, which excludes creatinine, and modified EASIX [m-EASIX], which replaces creatinine with CRP [mg/dL]), calculated peri-CAR T-cell infusion, would be associated with development of severe (grade ≥ 3) CRS and ICANS. We included 118 adults, 53 with B-acute lymphoblastic leukemia treated with 1928z CAR T cells (NCT01044069) and 65 with diffuse large B-cell lymphoma treated with axicabtagene ciloleucel or tisagenlecleucel. The 3 formulas showed similar predictive power for severe CRS and ICANS. However, low PLTs and high CRP values were the only variables individually correlated with these toxicities. Moreover, only m-EASIX was a significant predictor of disease response. m-EASIX could discriminate patients who subsequently developed severe CRS preceding the onset of severe symptoms (area under the curve [AUC] at lymphodepletion, 80.4%; at day -1, 73.0%; and at day +1, 75.4%). At day +3, it also had high discriminatory ability for severe ICANS (AUC, 73%). We propose m-EASIX as a clinical tool to potentially guide individualized management of patients at higher risk for severe CAR T-cell-related toxicities.
引用
- Pennisi M, Sanchez-Escamilla M, Flynn JR, et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021. PMID: 34432870. doi:10.1182/bloodadvances.2020003885
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。